Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a
- PMID: 12373573
- DOI: 10.1007/s00431-002-1005-x
Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a
Abstract
Glycogen storage disease type 1a (GSD-1a), characterized by growth retardation, hypoglycemia, hepatomegaly, kidney enlargement, hyperlipidemia, hyperuricemia, and renal dysfunction, is caused by deficiencies in glucose-6-phosphatase (G6Pase), a key enzyme in glucose homeostasis. Over the last 20 years, dietary therapies have greatly improved the prognosis of GSD-1a patients. However, the underlying pathological process remains uncorrected and the efficacy of dietary treatment is frequently limited by poor compliance. Therefore, long-term complications still develop in adult patients. To develop future therapeutic approaches for GSD-1a, we have generated G6Pase-deficient (G6Pase(-/-)) mice that mimic the pathophysiology of human GSD-1a patients. To evaluate the feasibility of gene replacement therapy for this disorder, we have infused recombinant adenovirus containing murine G6Pase gene (Ad-mG6Pase) into G6Pase(-/-) mice. While only 15% of G6Pase(-/-) mice under glucose therapy survived weaning, a 100% survival rate was achieved when G6Pase(-/-) mice were infused with Ad-mG6Pase and 90% of which lived to 3 months of age. Hepatic G6Pase activity in Ad-mG6Pase-infused mice was restored to 19% of that in G6Pase(+/+) mice at 7 through 14 post-infusion days. Ad-mG6Pase infusion also greatly improved growth of G6Pase(-/-) mice and normalized plasma glucose, cholesterol, triglyceride, and uric acid profiles. Further, liver and kidney enlargement were less pronounced with near normal levels of glycogen depositions in both organs.
Conclusion: our data demonstrate that a single administration of a recombinant adenovirus vector can alleviate the clinical manifestations of glycogen storage disease type 1a in mice, suggesting that this disorder in humans can potentially be corrected by gene therapy.
Similar articles
-
Correction of glycogen storage disease type 1a in a mouse model by gene therapy.J Biol Chem. 2000 Jan 14;275(2):828-32. doi: 10.1074/jbc.275.2.828. J Biol Chem. 2000. PMID: 10625614
-
Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.Gene Ther. 2006 Sep;13(17):1281-9. doi: 10.1038/sj.gt.3302774. Epub 2006 May 4. Gene Ther. 2006. PMID: 16672983
-
Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.Mol Ther. 2007 Jul;15(7):1253-8. doi: 10.1038/sj.mt.6300188. Epub 2007 May 15. Mol Ther. 2007. PMID: 17505475
-
The molecular basis of type 1 glycogen storage diseases.Curr Mol Med. 2001 Mar;1(1):25-44. doi: 10.2174/1566524013364112. Curr Mol Med. 2001. PMID: 11899241 Review.
-
Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.Curr Mol Med. 2002 Mar;2(2):121-43. doi: 10.2174/1566524024605798. Curr Mol Med. 2002. PMID: 11949931 Review.
Cited by
-
Updated Gene Therapy for Renal Inborn Errors of Metabolism.Genes (Basel). 2025 Apr 29;16(5):516. doi: 10.3390/genes16050516. Genes (Basel). 2025. PMID: 40428338 Free PMC article. Review.
-
Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies.Pediatr Discov. 2023;1(2):e3. doi: 10.1002/pdi3.3. Epub 2023 Jul 24. Pediatr Discov. 2023. PMID: 38370424 Free PMC article.
-
Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.Mol Ther. 2010 Sep;18(9):1592-8. doi: 10.1038/mt.2010.119. Epub 2010 Jun 22. Mol Ther. 2010. PMID: 20571544 Free PMC article.
-
A detailed characterization of the adult mouse model of glycogen storage disease Ia.Lab Invest. 2009 Sep;89(9):1032-42. doi: 10.1038/labinvest.2009.64. Epub 2009 Jul 6. Lab Invest. 2009. PMID: 19581879 Free PMC article.
-
DBS Screening for Glycogen Storage Disease Type 1a: Detection of c.648G>T Mutation in G6PC by Combination of Modified Competitive Oligonucleotide Priming-PCR and Melting Curve Analysis.Int J Neonatal Screen. 2021 Nov 16;7(4):79. doi: 10.3390/ijns7040079. Int J Neonatal Screen. 2021. PMID: 34842616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical